"|Year Established: 1980."

During the past decade, Retinal Diagnostic Center conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 15 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 13 clinical trials were completed. i.e. 130% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retinal Diagnostic Center" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Jaeb Center for Health Research" with 6 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retinal Diagnostic Center" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "National Institutes of Health (NIH)" with 4 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Retinal Diagnostic Center" are "Diabetic Macular Edema" (6 trials), "Geographic Atrophy" (6 trials), "Macular Degeneration" (4 trials), "Macular Edema" (3 trials) and "Age-Related Macular Degeneration" (1 trials). Many other conditions were trialed in "Retinal Diagnostic Center" in a lesser frequency.

Most popular intervention types in "Retinal Diagnostic Center" are "Drug" (24 trials), "Other" (8 trials), "Procedure" (6 trials), "Biological" (3 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (9 trials), "Faricimab" (8 trials), "Aflibercept" (4 trials), "Placebo" (4 trials) and "Ranibizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Retinal Diagnostic Center" are 31 trials for "All" genders.

Currently, there are NaN active trials in "Retinal Diagnostic Center". undefined are not yet recruiting, 2 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Retinal Diagnostic Center, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Retinal Diagnostic Center, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".